This 2020 Middle East Summit on Residual Cardiovascular Risk is a comprehensive educational campaign targeted to meet the educational needs of medical professionals in clinical practice engaged in the prevention or the management of patients demonstrating risk or with established cardiovascular disease. 

By participating in these educational offerings, the learner is expected to be able to:

1) Identify opportunities to address ASCVD residual risk factors, including under-treatment of related conditions and non-LDL related risk conditions

2) Describe the association of LDL-C driven RR with ASCVD RR, including the role of intensive LDL lowering on risk reduction 

3) Select evidence-based residual risk reduction interventions, including modifying TGL

4) Distinguish glucose-lowering agents associated with independent ASCVD risk reduction effects, including GLP-1 receptor agonists and SGLT2 inhibitors

5) List the pros and cons of more intensive blood pressure lowering with regards to RR

6) Describe the epidemiology and association of CKD especially in diabetic and or hypertensive individuals with cardiovascular disease 

7) Recall the association of Lp(a) with ASCVD Risk, epidemiology, genetics and identify upcoming clinical trials exploring the use of specific Lp(a) inhibitors.

8) Identify biomarkers associated with inflammation-driven ASCVD RR, including CRP and design inflammation management plans to reduce RR, including exercise and weight loss

9) Describe the association of increased thrombotic RR with ASCVD, including the role of dual antiplatelet therapy, single antiplatelet or dual antiplatelet therapy plus low-dose NOAC in reducing RR 

The IAS is proud to present this esteemed global faculty.  More information on each faculty member can be found here.

Khalid Al-Rasadi, MD

Raul D Santos, MD, MSc, PhD

Tarek M Fiad, MBBCh, FRCPI, FRCP, MD

There are no Disclosure Statements against this Module for Tarek M Fiad, MBBCh, FRCPI, FRCP, MD

Dr. Hani Sabbour, MD, FACC, FHRS, FASE

Dr. Rabih R. Azar, MD, MPH, FACC

Omar M. Hamoui, MD

Dr. Abdullah Shehab

There are no Disclosure Statements against this Module for Dr. Abdullah Shehab

Dr. Khalid Al Habib

There are no Disclosure Statements against this Module for Dr. Khalid Al Habib

Staff Disclosures

Staff involved with the development of this activity have nothing to disclose.

Moderator disclosures

Dr Fahad Al Nouri

Dr. Niaz Khan

There are no Disclosure Statements against this Module for Dr. Niaz Khan

Dr Wael Al Mahmeed

There are no Disclosure Statements against this Module for Dr. Wael Al Mahmeed

Dr Malek Mohamed

There are no Disclosure Statements against this Module for Dr. Malek Mohamed

Dr Abdul Majeed Brek Al Zubaidi

There are no Disclosure Statements against this Module for Dr. Malek Mohamed

The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the faculty and clinician attendees from throughout the Middle East who shared their experience and contributed to the IAS in its global mission.

When viewing each activity look for “Materials” tab to download PDF Slides